Teachers Advisors LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,026 shares of the medical technology company’s stock after purchasing an additional 64,447 shares during the period. Teachers Advisors LLC owned approximately 0.18% of Stryker worth $104,211,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Stryker by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 3,159,538 shares of the medical technology company’s stock worth $488,110,000 after purchasing an additional 85,614 shares during the period. Jensen Investment Management Inc. grew its stake in Stryker by 0.3% in the fourth quarter. Jensen Investment Management Inc. now owns 2,478,958 shares of the medical technology company’s stock valued at $383,842,000 after acquiring an additional 6,482 shares during the period. Lazard Asset Management LLC grew its stake in Stryker by 15.5% in the fourth quarter. Lazard Asset Management LLC now owns 2,208,379 shares of the medical technology company’s stock valued at $341,945,000 after acquiring an additional 296,550 shares during the period. Legal & General Group Plc grew its stake in Stryker by 2.8% in the third quarter. Legal & General Group Plc now owns 1,805,572 shares of the medical technology company’s stock valued at $256,393,000 after acquiring an additional 49,143 shares during the period. Finally, Wells Fargo & Company MN grew its stake in Stryker by 4.8% in the third quarter. Wells Fargo & Company MN now owns 1,742,959 shares of the medical technology company’s stock valued at $247,536,000 after acquiring an additional 79,551 shares during the period. 75.71% of the stock is owned by institutional investors and hedge funds.
Stryker Co. (SYK) opened at $167.11 on Wednesday. Stryker Co. has a 12-month low of $129.82 and a 12-month high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The company has a market capitalization of $62,898.64, a P/E ratio of 62.35, a PEG ratio of 2.41 and a beta of 0.70.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date is Wednesday, March 28th. Stryker’s dividend payout ratio is currently 70.15%.
In other Stryker news, VP Yin C. Becker sold 23,221 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the completion of the sale, the vice president now directly owns 10,499 shares in the company, valued at $1,742,414.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total value of $1,214,266.00. The disclosure for this sale can be found here. Insiders have sold 43,611 shares of company stock valued at $7,178,719 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.
A number of research analysts have issued reports on SYK shares. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $161.00 to $173.00 in a research note on Thursday, November 16th. SunTrust Banks reissued a “buy” rating and issued a $161.00 target price on shares of Stryker in a research note on Friday, November 17th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Thursday, December 7th. Finally, BMO Capital Markets raised Stryker to a “market perform” rating and set a $163.00 target price for the company in a research note on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $163.85.
ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/03/14/teachers-advisors-llc-has-104-21-million-position-in-stryker-co-syk.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.